尼洛替尼一线治疗慢性髓系白血病的进展  

Nilotinib in first-line treatment of chronic myeloid leukemia

作　　者：洪梨 王玉[1] 张琦[1] 吕成芳[1] Hong Li;Wang Yu;Zhang Qi;Lyu Chengfang(Department of Hematology,First Affiliated Hospital of Harbin Medical University,Harbin 150001,China)

机构地区：[1]哈尔滨医科大学附属第一医院血液内科,150001

出　　处：《国际肿瘤学杂志》2020年第1期56-59,共4页Journal of International Oncology

摘　　要：慢性髓系白血病(CML)是一类骨髓增殖性肿瘤,其发病机制与BCR/ABL融合基因相关。酪氨酸激酶抑制剂(TKI)可显著改善CML患者的生存及预后。尼洛替尼一线治疗CML患者疗效显著、治疗反应快、缓解程度深并且安全性高。在获得持续深层分子反应后,实现停止尼洛替尼用药并达到无治疗缓解是CML治疗的新目标。此外,由于疾病耐药及突变的产生,尼洛替尼治疗失败后如何开始新的治疗值得进一步研究。Chronic myeloid leukemia(CML)is a myeloproliferative tumor whose pathogenesis is related to the BCR/ABL fusion gene.Tyrosine kinase inhibitors(TKIs)can significantly improve the survival and prognosis of CML patients.Nilotinib is effective in first-line treatment of CML patients with rapid response,deep remission and high safety.After achieving a sustained deep molecular response,it is a new therapeutic goal for CML to stop the use of nilotinib and achieve treatment-free remission.In addition,due to disease resistance and mutations,how to start new treatments after nilotinib treatment failure is worth further research.

关 键 词：白血病 髓样 慢性期 酪氨酸激酶抑制剂 尼洛替尼 

分 类 号：R73[医药卫生—肿瘤]